Tempted by the Glaxo share price? Here’s what you need to know

Shares in GlaxoSmithKline plc (LON:GSK) look tempting after their recent rally, but you should read this before you buy the stock.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GlaxoSmithKline (LSE: GSK) share price has achieved one of the best performances of any FTSE 100 stock this year. 

Over the past 12 months, shares in the pharmaceutical giant have yielded a total return for investors of 16.1%, outperforming the Footsie by 13.5%. 

Following this performance, the Glaxo share price looks hugely tempting, but are the shares undervalued at current levels? Today I’m going to try and figure this out.

Dramatic turnaround

Glaxo’s CEO is almost entirely responsible for the company’s spectacular performance over the past year. Emma Walmsley was appointed group CEO after Sir Andrew Witty retired in March 2017. She inherited a firm that had a global reputation, but that lacked a strategic focus. Walmsley didn’t waste any time changing the direction of the business.

Since taking over, she’s outlined a new road map for the company’s consumer pharmaceuticals business, presided over the substantial acquisition of Tesaro and re-focused Glaxo’s research and development teams. 

The new CEO has also outlined plans to break up the business at some point in the next few years. This is something the City has been pushing for some time. 

Breakup on the cards 

After Glaxo announced the £10bn joint venture with its US rival Pfizer to combine the two groups’ consumer healthcare businesses, management revealed that when the deal is complete, it will de-merge and float the enterprise. 

The deal closed late last month. Glaxo has a 68% ownership stake with Pfizer owning the remainder. The combined entity will have sales of as much as £10bn and could yield cost savings of £500m by 2022. 

The two partners want to spin off the new business within three years of completing the deal. So, on that time frame, it looks as if the de-merger will take place in 2022. 

And when it does, it could unlock a lot of value for shareholders. Some analysts have suggested that on a sum-of-the-parts basis, the Glaxo share price is worth more than 2,000p. Unlocking value through a break-up makes it more likely that at this price target will be realised.

Unlocking value

The possibility of a break-up is the primary reason why I think the Glaxo share price could be a great addition to your portfolio.

While the stock might look quite expensive compared to the rest of the market at current levels, the break-up value suggests that anything below 2,000p is a good deal. 

The stock is currently trading at a forward P/E of 15 compared to the UK pharmaceutical average of 17. It also supports a dividend yield of 4.6%. 

Including this income, based on the assumption that the Glaxo share price will hit 2,000p by 2020, I calculate investors could pocket a return of 30% over the next three years or 10% per annum. Because the FTSE 100 has produced an average annual return of 7% for the past 10 years, this yield looks highly attractive to me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »